Apellis Slashes Costs To Focus On Troubled Syfovre Launch
Cuts To Jobs And Pipeline
The blockbuster-tipped eye therapy Syfovre has hit safety doubts and Apellis is streamlining to give more support to the drug’s global launch.
The blockbuster-tipped eye therapy Syfovre has hit safety doubts and Apellis is streamlining to give more support to the drug’s global launch.